REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...
Neon Therapeutics is a clinical-stage immuno-on...
CrowdMedâs patented prediction market technology can uncover diagnoses to real-w...
CrowdMedâs patented prediction market technol...
Exact Sciences Corp. (NASDAQ: EXAS) is committed to playing a role in the eradicat...
Exact Sciences Corp. (NASDAQ: EXAS) is committe...
NuVasive is a world leader in minimally invasive, procedurally integrated spine so...
NuVasive is a world leader in minimally invasiv...
Nemaura Medical (NASDAQ:NMRD) is a medical technology company which has developed ...
Nemaura Medical (NASDAQ:NMRD) is a medical tech...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
Adverum is a clinical-stage gene therapy company targeting unmet medical need in o...
Adverum is a clinical-stage gene therapy compan...
Join the National Investor Network and get the latest information with your interests in mind.